(Q81369539)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16233938%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Versatile and efficient synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16233938%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

Andrew Lees

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16233938%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Goutam Sen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16233938%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Alberto LopezAcosta

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16233938%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

12 September 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16233938%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16233938%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16233938%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16233938%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

716-729

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16233938%20AND%20SRC:MED&resulttype=core&format=json

T cell independent antigens

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Bacterial meningitis in the United States in 1995. Active Surveillance Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Glycoprotein conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Re.: Trinitrophenyl-protein conjugates are more complex than it is currently thought

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

7 January 2021

Tissue sulfhydryl groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micromethod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Virulence, immunity, and vaccine related to Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

A colorimetric determination of aminooxy acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

A chemoselective method for site-specific immobilization of peptides via aminooxy group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

A spectrophotometric assay for soluble and immobilized N-hydroxysuccinimide esters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysacch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Preparation of protein conjugates via intermolecular hydrazone linkage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

High yield, site-specific coupling of N-terminally modified beta-lactamase to a proteolytically derived single-sulfhydryl murine Fab'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Natural peptides as building blocks for the synthesis of large protein-like molecules with hydrazone and oxime linkages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

A novel method for the rational construction of well-defined immunogens: the use of oximation to conjugate cholera toxin B subunit to a peptide-polyoxime complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Multivalent poly(ethylene glycol)-containing conjugates for in vivo antibody suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

A synthetic peptide-based polyoxime vaccine construct of high purity and activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Assembly of synthetic peptide vaccines by chemoselective ligation of epitopes: influence of different chemical linkages and epitope orientations on biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Use of an aminooxy linker for the functionalization of oligodeoxyribonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

3′-Oligonucleotides conjugation via chemoselective oxime bond formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Synthesis of peptide-oligonucleotide conjugates with single and multiple peptides attached to 2'-aldehydes through thiazolidine, oxime, and hydrazine linkages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Synthesis of N-Fmoc-O- (N'-Boc-N'-methyl)-aminohomoserine, an amino acid for the facile preparation of neoglycopeptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

A Versatile Set of Aminooxy Amino Acids for the Synthesis of Neoglycopeptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Aminooxy-, Hydrazide-, and Thiosemicarbazide-Functionalized Saccharides: Versatile Reagents for Glycoconjugate Synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

A highly convergent approach to O- and N-linked glycopeptide analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Solution and solid-phase chemoselective synthesis of (1-6)-amino(methoxy) di- and trisaccharide analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Expedient synthesis of aminooxylated-carbohydrates for chemoselective access of glycoconjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Synthesis of fluorescent probes for the detection of abasic sites in DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Synthesis of a New Heterobifunctional Linker, N-[4-(Aminooxy)butyl]maleimide, for Facile Access to a Thiol-Reactive 18F-Labeling Agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Synthesis of 1-(aminooxy)-4-[(3-nitro-2-pyridyl)dithio]butane and 1-(aminooxy)-4-[(3-nitro-2-pyridyl)dithio]but-2-ene, novel heterobifunctional cross-linking reagents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Mild tagging procedures for the structural analysis of glycans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Antibody response to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

7 January 2021

Synthetic trimer and tetramer of 3-beta-D-ribose-(1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

7 January 2021

Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

7 January 2021

Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

7 January 2021

Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.096

7 January 2021

10.1016/J.VACCINE.2005.08.096

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16233938%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference